Version: 1.0.0 | Published: 8 Oct 2024 | Updated: 229 days ago
Documentation
Description:
Phase II single arm study evaluating the activity of nilotinib in rare c-KIT mutated acral and mucosal melanoma (AMM). Entry into the trial is a 2 step process. Patients presenting with AMM are first registered (Step 1) for screening including confirmation of c-KIT mutation status. Eligible patients who proceed to study entry (step 2) commence treatment with nilotinib 400 mgs twice daily for as long as they continue to benefit from treatment.
Coverage
Spatial:
United Kingdom,England
Provenance
Temporal
Start Date:
01 January 2009
Time Lag:
Variable
Accessibility
Access
Access Rights:
Please contact the publisher using Contact Point details provided.
Access Request Cost:
Not specified
Delivery Lead Time:
Not applicable
Data Controller:
The Institute of Cancer Research
Usage
Resource Creators:
In Progress
Format and Standards
Vocabulary Encoding Schemes:
LOCAL
Languages:
en
Formats:
In Progress